GLG Law Newsletter:
What’s Happening with Carbon Removal?

The push to reduce carbon emissions isn’t enough. Hundreds of companies are now trying to remove carbon from the atmosphere entirely. Among the promising developments is direct air capture, a technology that absorbs and locks up CO2 from the air.

The U.S. government has drawn its support for carbon removal with the Bipartisan Infrastructure Law funding direct carbon capture hubs and programs, and the Inflation Reduction Act (IRA), including provisions to purchase carbon removal credits at $180 a cubic ton.

While the lion’s share of the capital for carbon removal comes from compliance markets and government investment, voluntary carbon credit markets are another innovation, with some of the largest purchasers being marketplaces themselves. The total volume in the voluntary market is only $1 billion a year, but that could grow to $10-$25 billion by 2030.

To better understand what’s happening with carbon removal, we spoke with Michael Blakemore, GLG Network Member and former Project Director at KBR with more than 25 years’ experience in the energy, resources, chemicals, and infrastructure sectors.

I hope you find it insightful.

Thank you,
David Solomon

P.S. If you’d like to receive the monthly newsletter straight in your inbox, subscribe here.

Is It Time for Carbon Removal?
Hundreds of companies are trying not just to sequester that carbon but to remove it from the atmosphere entirely. Innovations in technology, natural strategies, and legislative support have turned carbon removal projects into a growing market.
Finding an Expert Witness to Evaluate Molecular Lab Equipment

During the COVID-19 pandemic, a law firm sought an expert witness with experience in molecular diagnostic lab equipment. GLG sourced and placed a New York-based medical executive with more than 10 years of experience with clinical lab equipment and laboratory assessments. The expert provided a verbal opinion before being named on the designation date.

State of Pharma CDMOs
The State of Pharma Contract Development and Manufacturing Organizations

When we talk about contract drug and manufacturing organizations (CDMOs), we are really talking about a diverse group of companies that serve pharma/biotech/academia in a variety of ways, from discovery through to commercialization opportunities.

What We Can Do about Wasted Pharmaceuticals

The pharmaceutical industry incinerates billions of dollars’ worth of unopened, unused, and unexpired drugs each year in America. This waste leads to both economic and environmental challenges. The good news is the problems companies create when they destroy unused medicine aren’t difficult to solve.

Get the GLG Law Newsletter Straight to Your Inbox

Stay informed with a monthly curation of litigation trends, key learnings from industry leaders, and exclusive expert-led events.